What is it about?
Respiratory syncytial virus (RSV) causes lower respiratory tract infections with a high serious disease burden in infants and older adults. This report describes RSV genomic surveillance results from 2 large US healthcare networks in the first season after the introduction of RSV vaccines.
Featured Image
Photo by Ed Us on Unsplash
Why is it important?
Study strengths include whole genome viral sequencing from adults in 2 large geographically diverse US surveillance networks with linkage to verified vaccination status.
Perspectives
Continued genomic surveillance should continue as community uptake of RSV prevention products increases.
Dr. Cynthia Lucero-Obusan
U.S. Department of Veterans Affairs
Read the Original
This page is a summary of: Genomic Characterization of RSV in the US by Vaccination Status, JAMA, March 2025, American Medical Association (AMA),
DOI: 10.1001/jama.2025.1225.
You can read the full text:
Contributors
The following have contributed to this page
